"Cholangiocarcinoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant tumor arising from the epithelium of the BILE DUCTS.
Descriptor ID |
D018281
|
MeSH Number(s) |
C04.557.470.200.025.450
|
Concept/Terms |
Cholangiocarcinoma- Cholangiocarcinoma
- Cholangiocarcinomas
- Cholangiocellular Carcinoma
- Carcinoma, Cholangiocellular
- Carcinomas, Cholangiocellular
- Cholangiocellular Carcinomas
Extrahepatic Cholangiocarcinoma- Extrahepatic Cholangiocarcinoma
- Cholangiocarcinoma, Extrahepatic
- Cholangiocarcinomas, Extrahepatic
- Extrahepatic Cholangiocarcinomas
Intrahepatic Cholangiocarcinoma- Intrahepatic Cholangiocarcinoma
- Cholangiocarcinoma, Intrahepatic
- Cholangiocarcinomas, Intrahepatic
- Intrahepatic Cholangiocarcinomas
|
Below are MeSH descriptors whose meaning is more general than "Cholangiocarcinoma".
Below are MeSH descriptors whose meaning is more specific than "Cholangiocarcinoma".
This graph shows the total number of publications written about "Cholangiocarcinoma" by people in this website by year, and whether "Cholangiocarcinoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 1 | 1 |
1997 | 0 | 1 | 1 |
1999 | 2 | 0 | 2 |
2000 | 1 | 0 | 1 |
2002 | 4 | 2 | 6 |
2003 | 3 | 1 | 4 |
2004 | 7 | 2 | 9 |
2005 | 2 | 2 | 4 |
2006 | 6 | 3 | 9 |
2007 | 13 | 1 | 14 |
2008 | 7 | 3 | 10 |
2009 | 6 | 2 | 8 |
2010 | 8 | 2 | 10 |
2011 | 13 | 0 | 13 |
2012 | 7 | 3 | 10 |
2013 | 3 | 2 | 5 |
2014 | 6 | 0 | 6 |
2015 | 5 | 1 | 6 |
2016 | 6 | 3 | 9 |
2017 | 13 | 1 | 14 |
2018 | 8 | 3 | 11 |
2019 | 6 | 1 | 7 |
2020 | 14 | 3 | 17 |
2021 | 19 | 0 | 19 |
2022 | 20 | 0 | 20 |
2023 | 23 | 0 | 23 |
2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cholangiocarcinoma" by people in Profiles.
-
CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon. JCI Insight. 2024 Jan 23; 9(2).
-
Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers. Clin Cancer Res. 2023 12 01; 29(23):4853-4862.
-
Convergent MAPK pathway alterations mediate acquired?resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. J Hepatol. 2024 Feb; 80(2):322-334.
-
Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors. Oncologist. 2023 Nov 02; 28(11):928-943.
-
USP1 promotes cholangiocarcinoma progression by deubiquitinating PARP1 to prevent its proteasomal degradation. Cell Death Dis. 2023 10 11; 14(10):669.
-
Independent of Primary Sclerosing Cholangitis and Cirrhosis, Early Adulthood Obesity Is Associated with Cholangiocarcinoma. Cancer Epidemiol Biomarkers Prev. 2023 10 02; 32(10):1338-1347.
-
Great Debates: Neoadjuvant Therapy Should be Routinely Given for High-Risk Cholangiocarcinoma. Ann Surg Oncol. 2023 12; 30(13):7960-7965.
-
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. Cancer Discov. 2023 09 06; 13(9):2012-2031.
-
What Role Does Radiotherapy Play in the Molecular Era for Intrahepatic Cholangiocarcinoma? Cancer J. 2023 Sep-Oct 01; 29(5):272-278.
-
The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma. JCO Precis Oncol. 2023 08; 7:e2200594.